Anavex Life Sciences Corp. reported its financial results for the third fiscal quarter of 2025, which ended June 30, 2025. The company announced a net loss of $13.2 million, or $0.16 per share, for the quarter.
Christopher U. Missling, PhD, President and CEO of Anavex, stated that the development of non-invasive, targeted upstream compounds continues to advance, particularly in the context of Alzheimer’s disease. He noted that clinical feedback highlights the importance of orally administered therapies that are both accessible and effective.
The company recently presented open-label extension data for blarcamesine at AAIC 2025, which demonstrated continued clinically meaningful benefit in early-stage Alzheimer’s patients, further validating its therapeutic potential. The financial information for the quarter is available on the company’s website and through SEC filings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.